Viracta Therapeutics, Inc.
VIRX · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.01 | -0.00 | 0.29 |
| FCF Yield | -181.82% | -64.34% | -19.86% | -6.22% |
| EV / EBITDA | -0.75 | -0.90 | -0.16 | -11.62 |
| Quality | ||||
| ROIC | -115.54% | -59.15% | 110.34% | -43.78% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 73.33% |
| Cash Conversion Ratio | 0.78 | 0.72 | 0.16 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -20.30% |
| Free Cash Flow Growth | -12.75% | -53.67% | -43.42% | 27.39% |
| Safety | ||||
| Net Debt / EBITDA | -0.28 | 0.24 | 0.86 | 2.18 |
| Interest Coverage | -13.69 | -87.68 | 127.30 | -87.11 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -0.23 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,810.90 | -5,996.43 | -5,948.68 | -17,759.53 |